Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications

[1]  S. Ständer,et al.  Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  S. Kwatra,et al.  Health-related quality of life and economic burden of chronic pruritus. , 2020, The Journal of investigative dermatology.

[3]  G. Yosipovitch,et al.  Practical approaches for diagnosis and management of prurigo nodularis: US expert panel consensus. , 2020, Journal of the American Academy of Dermatology.

[4]  S. Kwatra,et al.  Intranasal Butorphanol Rescue Therapy for the Treatment of Intractable Pruritus: A Case Series from the Johns Hopkins Itch Clinic. , 2020, Journal of the American Academy of Dermatology.

[5]  Arul James,et al.  Basic Opioid Pharmacology — An Update , 2020, British journal of pain.

[6]  L. Skov,et al.  Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study , 2020, Acta dermato-venereologica.

[7]  J. Szepietowski,et al.  Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  Annemarie Cesta,et al.  Development and Validation of a Uremic Pruritus Treatment Algorithm and Patient Information Toolkit in Patients with Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). , 2020, Journal of pain and symptom management.

[9]  Sewon Kang,et al.  Real-world prevalence of prurigo nodularis and burden of associated diseases. , 2020, The Journal of investigative dermatology.

[10]  F. Menzaghi,et al.  Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients , 2020, Kidney international reports.

[11]  G. Yosipovitch,et al.  A New Generation of Treatments for Itch , 2020, Acta dermato-venereologica.

[12]  F. Menzaghi,et al.  A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. , 2019, The New England journal of medicine.

[13]  T. Khan,et al.  Impact of Pruritus on Sleep Quality of Hemodialysis Patients: A Systematic Review and Meta-Analysis , 2019, Medicina.

[14]  G. Yosipovitch,et al.  Chronic itch management: therapies beyond those targeting the immune system. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  H. Javed,et al.  Uremic Pruritus: Prevalence and Impact on Quality of Life and Depressive Symptoms in Hemodialysis Patients. , 2019, Cureus.

[16]  Tito D. Tubog,et al.  Prophylactic Nalbuphine to Prevent Neuraxial Opioid-Induced Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2019, Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses.

[17]  T. Hashimoto,et al.  Itch: From mechanism to (novel) therapeutic approaches , 2018, The Journal of allergy and clinical immunology.

[18]  N. Volkow,et al.  Untangling the complexity of opioid receptor function , 2018, Neuropsychopharmacology.

[19]  M. Gold,et al.  Kappa Opioid Receptor Distribution and Function in Primary Afferents , 2018, Neuron.

[20]  V. Mathur,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus , 2017, American Journal of Nephrology.

[21]  P. Jagodziński,et al.  Opioid Receptors in Psoriatic Skin: Relationship with Itch. , 2017, Acta dermato-venereologica.

[22]  F. He,et al.  The effect of naloxone treatment on opioid-induced side effects , 2016, Medicine.

[23]  Jungsoo Lee,et al.  Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus , 2016, Annals of dermatology.

[24]  J. Ansermino,et al.  A naloxone admixture to prevent opioid-induced pruritus in children: a randomized controlled trial , 2015, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[25]  T. Kaneko,et al.  Dynorphin Acts as a Neuromodulator to Inhibit Itch in the Dorsal Horn of the Spinal Cord , 2014, Neuron.

[26]  A. Claxton,et al.  Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms , 2013, International journal of nephrology and renovascular disease.

[27]  Y. Ueno,et al.  One year long-term study on abuse liability of nalfurafine in hemodialysis patients. , 2013, International journal of clinical pharmacology and therapeutics.

[28]  Z. Zou,et al.  Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials , 2013, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[29]  E. Tschachler,et al.  European S2k Guideline on Chronic Pruritus. , 2012, Acta dermato-venereologica.

[30]  S. Ständer,et al.  Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. , 2012, Acta dermato-venereologica.

[31]  Howard S. Smith,et al.  Peripherally acting opioids and clinical implications for pain control. , 2011, Pain physician.

[32]  T. Muramatsu,et al.  Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  G. Yosipovitch,et al.  Butorphanol for treatment of intractable pruritus. , 2006, Journal of the American Academy of Dermatology.

[34]  Y. Ueno,et al.  Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  L. Sumanovski,et al.  Changes of Epidermal Mu-Opiate Receptor Expression and Nerve Endings in Chronic Atopic Dermatitis , 2005, Dermatology.

[36]  N. Weidner,et al.  Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children , 2000, Paediatric anaesthesia.

[37]  E. Dunteman,et al.  Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. , 1996, Journal of pain and symptom management.

[38]  B. Kay,et al.  Nalbuphine , 1985, Reactions Weekly.

[39]  D. Jasinski,et al.  Evaluation of nalbuphine for abuse potential , 1972, Clinical pharmacology and therapeutics.

[40]  A. Cowan,et al.  Targeting Itch with Ligands Selective for κ Opioid Receptors. , 2015, Handbook of experimental pharmacology.

[41]  Lindsey M. Snyder,et al.  Itch and its inhibition by counter stimuli. , 2015, Handbook of experimental pharmacology.

[42]  M. Bishop,et al.  Epidural naloxone reduces pruritus and nausea without affecting analgesia by epidural morphine in bupivacaine , 2000, Canadian journal of anaesthesia = Journal canadien d'anesthesie.